<p>The comparison of P (EUR) and EA to medications used in the treatment of MS.</p
<p>Comparison between actual and predicted concentration using the FA-MLR and the SPA-MLR.</p
<p>Treatment and outcome data: Comparison of MARS and standard medical treatment (SMT).</p
<p>Comparison of the clinical effects between patients with complete VICC and partial VICC.</p
<p>Comparison of the score for the extent of neurological impairment, score of mRs and MMSE.</p
<p>The comparison of the value of leptin, adiponectin and L/A in the diagnose of MS and its componen...
<p>Comparison of CSF and blood parameters between patients with MS and other inflammatory CNS disord...
Comparisons of clinical outcome between the severe group and the moderate group.</p
Comparison of clinicopathological parameters between patients with and without RAI-avid mLN.</p
<p>Comparison between prescriptions of allopaths and physicians trained in alternative forms of medi...
Comparison of pharmacological data between patients with and without polypharmacy.</p
<p>Comparison of demographic and clinical characteristics of patients with multiple sclerosis (MS) a...
Cost-economic analysis comparison between patients in the two treatment arms.</p
<p>Comparison of subscale scores and summary scores using different scoring methods, by medication s...
Comparison of odds-ratio of different diagnostic codes among MS cohort vs. the general population.</...
Pharmaceutical innovation around the adoption of the Euro–difference-in-difference.</p
<p>Comparison between actual and predicted concentration using the FA-MLR and the SPA-MLR.</p
<p>Treatment and outcome data: Comparison of MARS and standard medical treatment (SMT).</p
<p>Comparison of the clinical effects between patients with complete VICC and partial VICC.</p
<p>Comparison of the score for the extent of neurological impairment, score of mRs and MMSE.</p
<p>The comparison of the value of leptin, adiponectin and L/A in the diagnose of MS and its componen...
<p>Comparison of CSF and blood parameters between patients with MS and other inflammatory CNS disord...
Comparisons of clinical outcome between the severe group and the moderate group.</p
Comparison of clinicopathological parameters between patients with and without RAI-avid mLN.</p
<p>Comparison between prescriptions of allopaths and physicians trained in alternative forms of medi...
Comparison of pharmacological data between patients with and without polypharmacy.</p
<p>Comparison of demographic and clinical characteristics of patients with multiple sclerosis (MS) a...
Cost-economic analysis comparison between patients in the two treatment arms.</p
<p>Comparison of subscale scores and summary scores using different scoring methods, by medication s...
Comparison of odds-ratio of different diagnostic codes among MS cohort vs. the general population.</...
Pharmaceutical innovation around the adoption of the Euro–difference-in-difference.</p
<p>Comparison between actual and predicted concentration using the FA-MLR and the SPA-MLR.</p
<p>Treatment and outcome data: Comparison of MARS and standard medical treatment (SMT).</p
<p>Comparison of the clinical effects between patients with complete VICC and partial VICC.</p
DOI
Add to ORKG